| 000 | 02778 a2200769 4500 | ||
|---|---|---|---|
| 005 | 20250515103541.0 | ||
| 264 | 0 | _c20080228 | |
| 008 | 200802s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2007.13.5939 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGuix, Marta | |
| 245 | 0 | 0 |
_aShort preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cFeb 2008 |
||
| 300 |
_a897-906 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xblood |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 |
_aErbB Receptors _xmetabolism |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aIn Situ Nick-End Labeling |
| 650 | 0 | 4 |
_aKi-67 Antigen _xmetabolism |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoadjuvant Therapy _xmethods |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNeoplasms, Hormone-Dependent _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xblood |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aQuinazolines _xblood |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xmetabolism |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xmetabolism |
| 650 | 0 | 4 |
_aReceptors, Progesterone _xmetabolism |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 | _aTandem Mass Spectrometry |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aGranja, Nara de Matos | |
| 700 | 1 | _aMeszoely, Ingrid | |
| 700 | 1 | _aAdkins, Theresa B | |
| 700 | 1 | _aWieman, Bobbye M | |
| 700 | 1 | _aFrierson, Kerek E | |
| 700 | 1 | _aSanchez, Violeta | |
| 700 | 1 | _aSanders, Melinda E | |
| 700 | 1 | _aGrau, Ana M | |
| 700 | 1 | _aMayer, Ingrid A | |
| 700 | 1 | _aPestano, Gary | |
| 700 | 1 | _aShyr, Yu | |
| 700 | 1 | _aMuthuswamy, Senthil | |
| 700 | 1 | _aCalvo, Benjamin | |
| 700 | 1 | _aKrontiras, Helen | |
| 700 | 1 | _aKrop, Ian E | |
| 700 | 1 | _aKelley, Mark C | |
| 700 | 1 | _aArteaga, Carlos L | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 26 _gno. 6 _gp. 897-906 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2007.13.5939 _zAvailable from publisher's website |
| 999 |
_c17690440 _d17690440 |
||